Iambic
Category: AI in Healthcare
A clinical-stage biotechnology company utilizing a physics-informed generative AI platform to accelerate the discovery and development of high-quality therapeutic candidates for oncology and other unmet medical needs. Iambic was founded in 2019. The company is led by Thomas Miller. Based in San Diego, USA. Team size: 100. Total funding raised: $308.3M+. Latest round: Series B. Key investors include NVIDIA (NVentures), Ascenta Capital, Sequoia Capital, Coatue, Freeflow Ventures, Takeda Ventures.
AMW Analysis
Iambic is a clinical-stage biotech founded in 2019 and based in San Diego, applying a physics-informed generative AI platform to drug discovery, with a focus on oncology and other areas of unmet medical need. Its approach pairs physics-based simulation with generative AI to identify therapeutic candidates with stronger drug-like properties and higher odds of clinical success, aiming to compress the traditional target-to-clinical-candidate timeline. The company has raised over $308.3 million to date, most recently through a Series B, backed by investors including NVIDIA (NVentures), Sequoia Capital, Coatue, Ascenta Capital, Freeflow Ventures, and Takeda Ventures.
Recent news flow shows the platform moving from technology validation toward clinical and commercial traction. A $100 million funding round in November 2025 coincided with its AI-designed cancer drug, IAM1363, advancing into Phase 1/1b trials and showing anti-tumor activity in heavily pretreated patients. That was followed in February 2026 by a $1.7 billion partnership with Takeda covering oncology and immunology drug discovery, built on AI models the company states have already moved candidates into clinical trials in under two years. Together, these developments mark a progression from early platform funding to a large-scale pharma collaboration.
AMW analysis, generated from 2 tracked news signals.
- Founded
- 2019
- Headquarters
- San Diego, USA
- Team size
- 100
- Total funding
- $308.3M+
Value proposition
Drastically reduces the timeline from target identification to clinical candidate by combining high-speed physics-based simulations with generative AI to identify molecules with superior 'drug-like' profiles and higher probabilities of clinical success.
Products and solutions
NeuralPlex: A proprietary AI platform for structural biology and molecular design., IAM1363: A highly selective, brain-penetrant small molecule HER2 inhibitor (Clinical Phase 1/1b)., IAM-C1: A potential best-in-class selective CDK2 inhibitor for solid tumors (IND-enabling stage)., Enzyme and Protein-Protein Interaction (PPI) discovery programs.
Unique value
Unlike traditional AI that relies solely on pattern recognition from existing data, Iambic uses 'physics-informed' AI which incorporates the fundamental laws of chemistry and physics to predict molecular behavior more accurately.
Target customer
Global pharmaceutical companies seeking R&D partnerships, and healthcare providers/patients within the oncology and neurology sectors.
Industries served
Biotechnology, Pharmaceuticals, Artificial Intelligence, Oncology, Neurology
Technology advantage
The platform achieves the accuracy of high-level quantum mechanical simulations at the speed of deep learning, allowing for the screening of billions of molecules while optimizing for multiple parameters (potency, selectivity, and safety) simultaneously.
How they differentiate
Iambic differentiates through its 'physics-informed' generative AI platform, NeuralPlex. Unlike competitors that rely solely on pattern recognition (AI) or computationally expensive simulations (Physics), Iambic combines the two to achieve quantum-mechanical accuracy at deep-learning speeds, specifically optimized for protein-ligand structure prediction.
Main competitors
Recursion Pharmaceuticals, Schrödinger, Insilico Medicine, Exscientia
Key partnerships
Takeda: A landmark $1.7 billion multi-target collaboration to discover and develop small-molecule therapeutics., NVIDIA: Strategic collaboration to optimize AI models and leverage advanced GPU computing for drug discovery., Lundbeck: Research collaboration focused on discovering novel therapeutics for neurological disorders., Illumina Ventures: Strategic investment and partnership for genomic-driven discovery., Jazz Pharmaceuticals: Research collaboration and drug-supply agreement (Oct 2025) to study IAM1363 combined with zanidatamab (Ziihera) in HER2-positive breast cancer., Revolution Medicines: Technology-enablement collaboration using Iambic's NeuralPLexer protein-ligand prediction platform.
Notable customers
Takeda Pharmaceutical, Lundbeck
Major milestones
Closed $100M Series B funding round led by Ascenta Capital and NVIDIA (Oct 2023), Entered Phase 1/1b clinical trials for IAM1363, a selective HER2 inhibitor (Early 2024), Signed a $1.7 billion multi-target strategic collaboration with Takeda (Feb 2024), Established research collaboration with Lundbeck for neurological disorder therapeutics
Growth metrics
Advanced lead program IAM1363 into Phase 1/1b clinical trials; expanded headcount to approximately 100 employees; secured a multi-billion dollar partnership pipeline.
Market positioning
Clinical-stage AI-biotech leader specializing in high-selectivity small molecule therapeutics for oncology and neurology.
Geographic focus
North America (Headquartered in San Diego), with strategic partnership reach in Europe and Asia.
Patents and IP
Holds a robust portfolio of patents covering its generative AI architectures (NeuralPlex), specific chemical matter for HER2 and CDK2 inhibitors, and proprietary methods for molecular property prediction.
About Thomas Miller
Thomas Miller is a renowned scientist and entrepreneur who served as a tenured Professor of Chemistry at the California Institute of Technology (Caltech) for over 130 peer-reviewed articles and patents. He co-founded Entos, Inc. (now Iambic Therapeutics) in 2019 to bridge the gap between AI and drug discovery. He holds a DPhil in Theoretical Chemistry from the University of Oxford and a BS from Texas A&M University.
Latest news about Iambic
- Takeda and Iambic Therapeutics have entered a $1.7 billion partnership to accelerate drug discovery for oncology and immunology. This collaboration utilizes AI models that have already demonstrated th
- Iambic's new $100M funding validates AI's transition from mere prediction to primary discovery in drug development. Their AI-designed cancer drug, IAM1363, is now advancing through Phase 1/1b clinical
More AI in Healthcare companies
Official website: https://www.iambic.ai
